Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Nektar says there have been manufacturing issues in two batches of experimental cancer drugs.
Let's see how the charts of GWPH are shaping up.
Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.
Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.
Three pharma distributors propose a $10 billion plan to a group of state attorneys general in opioid-abuse settlement.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.